Setmelanotide
RM-493 · Imcivree · C49H68N18O9S2 · monoisotopic 1116.4700 Da. The index holds 0 assay reports on this compound across 0 batches from 0 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
Setmelanotide is cyclised through a disulfide rather than a lactam, so its failure mode is reduction rather than incomplete cyclisation. Very thin coverage — the index has fewer than 25 records — and no per-supplier statistics are published.
- Compound class
- Melanocortin-receptor peptides
- Molecular formula
- C49H68N18O9S2
- Monoisotopic mass
- 1116.4700Da
- Average mass
- 1117.31Da
- Residues
- 8
- Nominal retention (RG-2, 30 min)
- 9.28min
- Retention window
- 0.25min
- Counter-ion as usually shipped
- acetate
- Typical label claims
- 5 mg · 10 mg
- Analytical difficulty (index scale)
- 1.00 — straightforward
- Purity is a defined quantity
- YES
What the index has observed
Arithmetic over the 0 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
The index holds no records for Setmelanotide carrying a purity figure. That is a gap in the index, not a finding about the compound.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| open-chain (reduced disulfide, +2 Da) | -0.58 | +2.016 | — | not observed | — |
| disulfide-scrambled isomer | +0.34 | mass-identical | — | not observed | — |
| oxidised Trp (+16 Da) | -0.32 | +15.995 | — | not observed | — |
| des-acetyl (−42 Da) | -0.44 | -42.011 | — | not observed | — |
Degradation pathways
- disulfide reduction
- Trp oxidation
Full impurity profile, with what each named species implies about the synthesis →
Clinical context
Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.
Setmelanotide is approved for obesity due to POMC, PCSK1 or LEPR deficiency and for Bardet–Biedl syndrome.
Quarterly coverage
Most recent records
No records yet. Submitting one is the only way this changes.